# Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus

> **NCT06913023** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 74 (estimated)

## Conditions studied

- Kidney Transplant Recipient

## Interventions

- **DRUG:** Semaglutide 3 MG [Rybelsus]
- **DRUG:** Semaglutide 7 MG [Rybelsus]
- **DRUG:** Semaglutide 14 MG [Rybelsus]
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT06913023
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-05
- **Primary completion:** 2027-11-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2025-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06913023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06913023, "Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06913023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*